Leqembi is an infusion therapy that targets and removes the beta-amyloid plaque that builds up in the brains of Alzheimer's ...

Copyright 2025 The Associated Press. All Rights Reserved. Actor Gene Hackman arrives with his wife, Betsy Arakawa, for the 60th Annual Golden Globe Awards in Beverly ...

In a report released on March 5, Seiji Wakao from J.P. Morgan maintained a Hold rating on Eisai Co (ESALF – Research Report), with a price target of Yen4,200.00. The company’s shares closed ...

NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.

This is the second time NICE made a decision not to approve these treatments for NHS use. Leqembi, marketed by Biogen and Eisai, was first rejected for NHS coverage in August 2024, while a ...

According to a survey conducted by Intuit Credit Karma, 80% of Americans have seen a noticeable increase in the price of groceries in the last few years, especially after the pandemic. No matter ...

The U.K.’s National Institute for Health and Care Excellence on Thursday again denied to recommend Biogen and Eisai’s Alzheimer’s disease therapy Leqembi, noting that its clinical benefits do not ...

were not considered for treatment with rituximab (Rituxan)/lenalidomide (Lenvima), and had an ECOG performance status of 0 or 1. 4 Patients were treated with intravenous (IV) odronextamab in 21-day ...

In August, NICE declined to recommend Biogen and Eisai’s Leqembi (lecanemab) for reimbursement. Three months later, NICE followed with the same decision on Lilly’s Kisunla (donanemab).

Good morning everyone, it’s Jason Mast, filling in for Ed. Today I’m in Pharmalittle’s New York bureau, sipping a cup poured from a French press gifted to me by my sisters, made from beans ...

Australia’s Therapeutic Goods Administration (TGA) has once again decided against approving Eisai Australia Pty Ltd.’s amyloid beta binder, Leqembi (lecanemab), for treating patients with mild ...